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AFIT-ENP-MS-15-M-089 
ABSTRACT 
Dengue is an emerging hemorrhagic fever virus and widely considered the most 
important arbovirus in the world [1].  The CDC and the World Health Organization 
estimates Dengue virus (DENV) infects 50-400 million people annually in the tropical 
and subtropical regions of the world [2].  More than 500 thousand of these will develop 
severe infection and approximately 22 thousand will lead to death [3].  DENV is a 
positive-sense RNA virus that exists in 4, potentially 5, antigenic serotypes.  An 
immunological phenomenon called antibody-dependent enhancement (ADE) leaves a 
DENV victim vulnerable to increased risk of subsequent infections.  Secondary infections 
with DENV are known to increase in severity from Dengue Fever to Dengue 
Hemorrhagic Fever or Dengue Shock Syndrome.  Currently, no vaccines or treatments 
are approved for DENV infections.  Unsuccessful vaccine trials open the door for non-
traditional treatments such as silver nanoparticles.  Silver nanoparticles (AgNP) are 
known to inhibit viral replication of numerous viruses but have never before been tested 
for inhibition of dengue virus type 2 (DENV2, ATCC® VR-1584™).  For the first time, 
this research presents up to a 96% reduction in DENV2 binding to Vero cells following 
pretreatment with AgNP (6-10nm, 25µg/mL).  These results suggest that similarly to 
other viruses, DENV2 can be inhibited at the first stage of the virus replication cycle, 
binding & entry.  
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HYPOTHESIS 
Null Hypothesis: Silver nanoparticles do not inhibit the binding step of the dengue virus 
serotype 2 (DENV2) replication cycle in Vero 76 cells, inferred through similar 
fluorescence intensity visualization. 
Alternate Hypothesis: Uncoated silver nanoparticles (8nm) inhibit the binding step of 
dengue virus serotype 2 (DENV2) replication cycle in Vero 76 cells, inferred through 
reduced fluorescence intensity visualization. 
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INTRODUCTION 
Dengue as a Global Threat 
Dengue is a disease caused by four closely related viruses known as dengue virus 
-1 through -4 (DENV1-DENV4).  A fifth serotype (DENV5) was discovered from a 
serological sample from 2007 but is not published.  Dengue fever is a disease that became 
prevalent in tropics during the great shipping industry expansion in the 18th and 19th 
centuries [4].  The principle arthropod vectors of dengue virus, the Aedes aegypti and 
Aedes albopictus mosquitoes, determine the geographic distribution of the disease.  
Approximately 40% of the world’s population (2.5 billion people) live in a region at risk 
of dengue [2].  Dengue is typically spread throughout the tropical and subtropical 
latitudes, but has demonstrated the ability to spread to new areas, such as Europe, 
Croatia, the United States, and Portuguese islands [2].  Based on the morbidity of dengue 
infection and the widespread presence of its vectors, DENV is considered the most 
important arbovirus (arthropod-borne virus) in the world [1]–[3].  Vector control is the 
primary means of stopping an outbreak and ending the disease transmission cycle. 
Dengue Pathology 
Dengue is transmitted through the bite of an infected female mosquito during its 
blood meal [5].  Humans are a dead-end host and the infection is not transmissible 
between humans.  A noninfected Aedes mosquito can become infected through a blood 
meal on an infected human.  After 4-10 days post-infection, a mosquito is an infectious 
vector for the remainder of its life [2].  The severity of an individual’s infection depends 
largely on the history of infection and is characterized by the three clinical categories – 
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dengue fever, dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).  
Primary infection may be asymptomatic or lead to classic dengue fever.  Secondary 
infections may lead to the serious conditions of DHF or DSS [1]. 
The World Health Organization estimates that 50-100 million people are infected 
with dengue each year.  Due to the lack in accurate and timely reporting and the absence 
of adequate medical facilities in endemic regions, other sources, such as the Centers for 
Disease Control (CDC) place this estimate as high as 400 million annual infections [3].  
Classic dengue fever is the predominant syndrome.  DHF accounts for over 500 thousand 
reported cases and there are over 22 thousand deaths annually [2]. 
Classic dengue fever is also known as “breakbone fever”, and was first described 
by Benjamin Rush during an outbreak in Philadelphia in 1780 [5].  Dengue fever begins 
after a 5-8 day incubation period with the abrupt onset of fever (103-1060F) and headache 
(Figure 1).  In the first day or two of fever, 
the face flushes and a generalized macular 
rash becomes evident.  Between days 4-6, 
symptoms include nausea, vomiting, 
anorexia, and swollen lymph nodes 
(lymphadenopathy).  The fever typically 
lasts 4-6 days and often culminates with a 
secondary maculopapular rash.  The level 
of viremia generally coincides with fever.  
 
Figure 1. Symptoms of dengue fever.  Public domain image, 
via Wikimedia Commons. 
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Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are severe 
forms of dengue infection that can lead to death.  DHF and DSS are common in areas 
with multiple endemic DENV serotypes.  These serious illnesses begin with typical 
dengue fever.  Severe symptoms follow 2-5 days later with petechiae, bruising, and large 
spontaneous bruising (ecchymosis). 
Table 1. World Health Organization grades of dengue fever (DF), hemorrhagic fever 
(DHF), or shock (DSS) [6]. 
Grade of 
disease 
Disease 
type 
Signs and Symptoms 
I DF 
Fever accompanied by nonspecific constitutional symptoms with 
a positive tourniquet test as the only hemorrhagic manifestation 
II DHF 
Same as grade I, except with spontaneous hemorrhagic 
manifestations 
III DSS 
Circulatory failure manifested by rapid, weak pulse with 
narrowing of the pulse pressure (<20 mmHg) or hypotension 
IV DSS Profound shock with undetectable blood pressure and pulse 
 
DHF and DSS are typically found in cases of secondary infection with a DENV 
serotype different from that of primary infection.  These clinical developments are 
brought on by an immunological phenomenon called antibody dependent enhancement 
(ADE).  For example, following a successful adaptive immune response to primary 
DENV1 infection, antibodies are created which recognize DENV1 epitopes and can assist 
only in the neutralization DENV1.  During a secondary infection with DENV2, the 
circulating antibodies that recognize DENV1 attach to the unfamiliar DENV2 particles 
and facilitate endocytosis by macrophages by means of the cognate (DENV-recognizing) 
receptors. However, the circulating antibodies only weakly activate the cellular defenses 
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and the virus will still undergo replication.  Additionally, the DENV1 antibodies bound to 
DENV2 particles will be able to bind and enter cells through the Fc (constant) receptors 
which are ubiquitously expressed.  This additional infectious pathway greatly contributes 
to the progressive symptoms of severe dengue (DHF/DSS). 
Dengue Threatens DOD Operations 
 The United States has military and civilian personnel stationed in many countries 
around the world.  Some of these locations are in regions where Dengue is endemic and a 
growing threat to the human population [3].  Although dengue fever is uncommon among 
US citizens, dengue is a top priority for health and medical services in endemic areas.  
Dengue has caused illness in US military personnel in every major conflict since the 
Spanish American War, excluding the recent Iraq and Afghanistan campaigns [7].  From 
the 1960s and through the 1990s, dengue infections were seen often in US 
servicemembers in Vietnam, the Philippines, Somalia, and Haiti.  In 1942, a dengue 
outbreak effected 80% of a single unit stationed in the Australian North Territory [7].  
Although the total number of cases in this outbreak was not documented, it casts a dark 
shadow in the potential for entire military units to be rendered incapable of performing 
their mission.  In 1944, over 24 thousand troops in New Guinea and approximately 20 
thousand in the Marshall Islands were confirmed to have dengue.  Throughout WWII, 
seventeen US bases were impacted by dengue [7]. 
 Dengue is a historic problem within the continental United States.  Between 1977 
and 1987, 1655 suspected cases of dengue were observed in the southern states, 345 of 
which were confirmed by serological tests.  These cases occurred long after dengue was 
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eliminated from the southern US in the 1920s.  This example shows that the potential for 
reintroduction of dengue still exists.  The most recent outbreaks of DENV occurred in 
Hawaii (2001), Texas (2005), and Florida (2014) [3]. 
Dengue as a Potential Bioterrorism Agent 
DENV is classified as a Biosafety Level 2 (BL-2) virus.  Some fear that biological 
agents could be used to contaminate water supplies.  DENV is not found naturally in 
water supplies and must infect living cells to replicate.  DENV is expected to survive in 
untreated water for short periods but not is not expected to survive common water 
treatment methods [8].  In this suspended form, DENV would not be infectious and 
requires parenteral transmission.  Dengue is only infectious through parenteral 
transmission which greatly limits the potential for non-vector dissemination.  Dengue 
does not exhibit rapid or morbid common in biowarfare agents and is not lethal unless 
severe shock or other complications are involved. 
Challenges to Dengue Therapeutics 
The design and implementation of a dengue vaccine is complicated by numerous 
factors.  First, the candidate vaccine must provide equal and lasting immune responses 
against all DENV serotypes.  This requires a tetravalent vaccine to address DENV1-4, 
and a pentavalent vaccine if the novel DENV5 is considered.  This vaccine would also 
need to solicit neutralizing antibodies regardless of the individuals existing immune 
status to DENV [6].  A second challenge is that there is not a validated correlate of 
protection.  Since the mechanism of DENV infection is not completely understood, the 
required antibody titers and impact of additional immunological pathways require further 
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study [9].  Third, an animal model does not exist which recapitulates both the disease 
outcome and a predictive immune response in humans.  Currently, mouse and non-human 
primate (NHP) models are used to evaluate vaccine candidates.  The mouse model 
requires modification of the viral genome to present clinical disease and may not be 
indicative of efficacy in humans.  The NHP model does not present clinical disease but 
does demonstrate viremia.  Possibly due to these factors, discordance is occasionally 
observed between preclinical and clinical trials [10]. 
Vaccines development is complicated by small mutations in DENV serotypes.  
One common mechanism of each DENV serotype and flaviviruses in general is the action 
of RNA-dependent RNA polymerase (RdRp).  This enzyme catalyzes the replication of 
RNA from the ss(+)RNA strand [11], [12].  Novartis developed an adenosine nucleoside 
inhibitor (NITD008) which directly inhibits the RdRp activity of DENV in vitro and in 
vivo.  NITD008 is an adenosine analog with several substitutions; a carbon for N-7 of the 
purine and an acetylene at the 2’ position of ribose [12].  Potential may exist for AgNP to 
inhibit DENV by binding to exposed disulfide motifs within DENV RdRp [11]. 
Nanoparticles as an Antiviral Treatment 
Nanoparticle therapeutics are in their infancy and there are currently no FDA 
approved nanotherapudics [13].  Several studies demonstrate the systemic effects of 
silver nanoparticles through various routes of exposure [14]–[17].  In a mouse model, 
inhalational and gastrointestinal exposure (1-3 months) to AgNP (20nm, citrate 
stabilized) did not show severe systemic toxicity but intravenous exposure has potential 
to suppress the functional immune system in a dose-dependent manner (0.0082-6 mg/mL) 
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[15].  Research also suggests that NP have potential to penetrate the blood-brain barrier 
(BBB) through intravenous and intraperitoneal exposure at high doses (25-100 mg/kg) 
[14]. 
These and similar studies offer unique insight to in vivo actions of AgNP but they 
do not offer broad applicability outside the structure of the research.  Published research 
involving AgNP does not consistently provide full characterization of the administered 
silver with respect to silver ion content, particle agglomeration, particle size distribution, 
surface coatings, or presence of synthesis byproducts.  Since these additional factors play 
a critical role in AgNP biocompatibility and in vivo response, such omissions reduce the 
transferability of those data.  Above certain concentrations (often >100µg/mL), AgNPs 
may exhibit genotoxic and cytotoxic effects in human tissue culture.  The possibility that 
this effect is due to higher concentration of silver ions must be considered.  This can lead 
to DNA damage, chromosomal aberrations, and cell death [18].  If AgNP are to be 
utilized in clinical settings, the applied concentration must be well characterized under in 
vivo applications and remain under the cytotoxic levels. 
LITERATURE REVIEW 
Dengue Virus Summary 
 DENV is a member of the Flavivirus family, as is the yellow fever virus (the 
family’s prototype), West Nile, Japanese encephalitis virus, and many others.  DENV is 
also categorized as a Group IV ss(+)RNA virus under the Baltimore Classification.  
Based on serological studies, five serotypes of DENV (DENV1-5) are known to exist 
[19], [20].  While DENV1-4 are in common circulation, DENV5 is known only to exist 
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in a single outbreak in Malaysia, presents challenges for the future of DENV vaccines 
and treatments.  Many scientists are skeptical about the serological independence of 
DENV5 and feel more research is necessary to determine if it is not a mutant of another 
DENV serotype [21].  These distinct serotypes present conserved structural and non-
structural proteins although the genome identity between serotypes ranges from 23-73% 
[22], [23].  DENV virions exist in one of four stages of maturation.  Only one of the four 
stages is infectious and considered mature.  The mature virions exist in the extracellular 
environment while the three immature virion forms are primarily found intracellularly. 
A mature DENV virion is composed of envelope proteins surrounding a 
nucleocapsid core which contains the viral genome.  The genome consists of a single, 
positive-sense strand of RNA, approximately 10.7kb in length.  The vRNA is translated 
into a single polyprotein. Viral and host proteases cleave this into three structural (C, 
prM, E) and seven non-structural (NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) proteins.  
The genome is surrounded by an icosahedral nucleocapsid C (capsid) protein 
approximately 30nm in diameter [5].  The nucleocapsid is disordered and associated with 
the vRNA in an overlapping region [24].  This core is surrounded by a lipid bilayer then a 
well-organized icosahedral envelope which consists of E-prM protein heterodimeric 
complexes [5], [25]. 
DENV successfully grows in many cells lines from vertebrate and invertebrate 
hosts, but the most common are the C6/36 (ATCC® CRL-1660™) derived from the 
Aedes albopictus mosquito and the Cercopithecus aethiops (African green monkey) 
kidney epithelial (Vero) cell lineage [5], [26].  Selection of the C6/36 cells for DENV 
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research is often preferable since they originate from the virus host.  The titer of DENV 
isolated from C6/36 cell propagation tends to higher and express less mutations than  
 isolates from Vero cells propagation [26].  However, as an invertebrate cell line, 
the utilization of C6/36 cells requires growth at 28oC.  Since this was a condition not 
supported at the researcher’s laboratory facility, Vero cells were selected as a suitable cell 
line for virus propagation and additional assays. 
Dengue Virus Binding and Entry 
Dengue virus binds to mammalian cells through a wide range of cell-surface 
receptors and co-receptors.  Among the known DENV receptors, heparin sulfate (Vero 
cells), DC-SIGN, and the mannose receptor (macrophages) appear to play a critical role 
[27]–[29].  In the event of antibody-dependent enhancement, the ubiquitous Fc receptor 
enhances DENV infection by binding anti-DENV antibodies and providing another entry 
pathway.  The DENV E protein (envelope glycoprotein) is the central epitope during 
binding.  Once bound to the cell, DENV is trafficked in a diffusive manner along the cell 
surface until reaching a pre-existing clathrin-coated pit [30].  Dengue entry into 
mammalian cells may occur through multiple mechanisms, dominated by clathrin-
mediated endocytosis and macropinocytosis [31], [32]. 
In the dominant case of clathrin-mediated endocytosis, DENV is internalized 
when the clathrin-coated pit invaginates and surrounds the particle.  Now considered an 
endosome, the pH is lowered through action of proton pumps.  The acidic pH causes a 
conformational change in the E protein below pH 6.2, causing it to become spiked in 
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appearance.  The hydrophobic tips of the spiked envelope proteins penetrate and fuse 
with the endosomal membrane, releasing the DENV genome into the cytoplasm. 
 Silver Nanoparticles as Antiviral Agents 
   During the course of this research, the interaction of AgNP with 10 virus 
species were identified (Table 2).  Each study concluded that AgNP inhibited the course 
of that particular virus replication cycle under certain conditions.  The mechanism of 
inhibition was not consistent between all viruses and some mechanisms are still 
unknown.  One common conclusion was that inhibitory mechanisms occurred early in the 
replication cycle, most commonly inhibiting the binding and entry of a virion into a host 
cell.   
 
Common experimental conditions which led to successful inhibition include: 
 Antiviral activity dependence on AgNP size 
 AgNP diameters between 8-25nm 
 AgNP concentrations between 8-50µg/mL 
 Tangential flow filtration (TFF) for AgNP size selection and silver ion removal 
I 
dsDNA 
II 
ssDNA 
III 
dsRNA 
IV 
ss(+)RNA 
V 
ss(-)RNA 
VI 
ssRNA-RT 
VII 
dsDNA-RT 
Vaccinia [33] 
Monkeypox [34] 
HSV2 [35] 
Adenovirus 
  **DENV 
H1N1 [36] 
H3N2 [37] 
TCRV [38] 
RSV [39] 
HIV-1 [40]–
[43] 
HBV [44] 
Table 2. Existing research silver nanoparticles as antiviral treatments.  Organized by Baltimore 
Classification.  **DENV is utilized for the first time in this research. 
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 AgNP which are naked or capped or stabilized with citrate, polyethylene glycol 
(PEG), or polyvinylpyrrolidone 
Vaccinia virus (VACV) 
Silver Nanoparticles demonstrated cytoprotective and virucidal effects during 
VACV infection of Vero cells [33], [43].  Adsorption of VACV was not prevented when 
Vero cells were pretreated with AgNP (11nm, 8-128µg/mL), as determined by plaque 
assay.  The entry of vaccinia virus into Vero cells is inhibited by AgNP at values above 
48µg/mL as determined by a β-gal (beta galactosidase) assay under the control of a 
constitutively active promoter.  Through confocal microscopy quantification, VACV 
entry was inhibited when pretreated > 16µg/mL.  VACV is an enveloped dsDNA virus 
that replicated entirely in the cytoplasm.  VACV is in the family Poxviridae and contains 
both a large genome (~190kbp) and large virion (~300nm).  VACV enters host cells 
through macropinocytosis and direct fusion. 
Monkeypox virus (MPV) 
MPV infection of Vero cells was inhibited by 10nm polysaccharide-coated AgNP 
[34].  AgNP in diameters of 10-80nm, concentrations from 12.5-100µg/mL, and either 
polysaccharide coated or naked were tested against MPV in plaque reduction assays.  
Only the 10nm PS-coated AgNP reduced mean PFU below control (P < 0.05).  This 
result is similar to HIV-1 studies with AgNP where smaller particles (1-10nm) provided 
the best antiviral activity.  Rogers, et al. suggest the small particles effectively bind to 
viral epitopes and block the binding complex between virus and cell surface receptors 
and co-receptors.  Another conclusion of this research was that the mechanism of 
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inhibition is unknown but may “involve blocking of MPV to host cells, disruption of host 
cell biochemical pathways, or both” [34].  MPV is similar to VACV in size and 
replication cycle.   
Herpes simplex virus (HSV) 
 AgNP of unspecified diameter and concentration reportedly inhibit HBV2 in Vero 
cells.  Sopova et al. described in the Russian journal (not translated to English) that 
“silver nanopowders” significantly reduced viral progeny in vitro.  HSV is an enveloped 
dsDNA virus (152kbp) that enters host cells through fusion.   
Adenovirus type 3 (ADV3) 
 Adenoviruses are non-enveloped dsDNA viruses with a diameter of 70–90 nm.  
ADV3 infection of HeLa cells was inhibited by AgNP (11.4+6.2nm) in concentrations 
from 3.125-50µg/mL [45].  Cytopathic effects were observed in in HeLa cells when 
AgNP concentrations exceeded 50µg/mL as seen in similar experiments. Unlike most 
AgNP antiviral experiments which treat cells and virus for 1 hour, Chen et al. treated for 
2 hours.  ADV3 that was treated with 50µg/mL AgNP for 30 minutes experienced 
conformational changes in the virion structure.  Treatment for 90 and 120 minutes created 
dramatic damage to the virion.  Unfortunately, the researchers did not mention whether 
their AgNP colloid contained significant levels of silver ions, the most likely cause of 
ADV3 damage. 
Influenza A (H1N1 and H3N2 IFV) 
H1N1 and H3N2 influenza A infection of Madin-Darby Canine Kidney epithelial 
(MDCK) cells was inhibited by non-coated AgNP [36], [37].  AgNP in these studies were 
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characterized in the range of 5-120nm (10nm mean).  This study found that when H1N1 
or H3N2 IFV were pretreated for 2 hours with AgNP concentrations of 12.5-50µg/mL, 
the viability of MDCK cells was significantly increased (P<0.01).  When virus was 
incubated with AgNP (50µg/mL) for 30-120 minutes, the IFV experienced structural 
damage.  Damage was observed even when there did not appear to be AgNP bound to 
virions, indicating damage through silver ions.  These studies recognized the potential 
significance of silver ions in an antiviral mechanism but did not present data on ion 
content in their colloid or any methods used to remove silver ions during 
experimentation. 
Tacaribe virus (TCRV) 
Tacaribe virus infection of Vero cells was inhibited by AgNP of varying size and 
coating [38].  AgNP (10nm and 25nm) that were either naked or polysaccharide-coated 
significantly inhibited viral progeny (P<0.05).  AgNP concentrations above 50µg/mL 
were determined to exhibit cytopathic effect.  Unlike other AgNP antiviral studies, TCRV 
experienced enhanced uptake into Vero cells when in complex with 10nm non-coated 
AgNP (50µg/mL).  Replication was inhibited after entry to the cell by an unknown 
mechanism. 
Respiratory syncytial virus (RSV) 
 RSV infection of HEp-2 cells was reduced by 44% after RSV pretreatment with 
poly(N-vinyl-2-pyrrolidone) (PVP) coated AgNP.  These functionalized AgNP exhibited 
low cytotoxicity at low concentrations. 
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Human immunodeficiency virus (HIV-1) 
Several studies have determined that HIV-1 (or HIV-1 pseudotyped virus [43]) 
binding and entry to host cells can be inhibited by AgNP pretreatment [40]–[43].  
Common conclusions indicate that AgNP (<25nm) bind to the glycoprotein 120 (gp120) 
knobs of the HIV-1 envelope but a 1-10nm diameter is optimal [42].  This binding event 
blocks the formation of the gp120-CD4 complex and inhibits cell fusion.  One study 
determined that the use of AgNP and neutralizing antibodies had an additive inhibitory 
effect against cell-associated HIV-1 [41]. 
Hepatitis B (HBV) 
AgNP (10nm & 50nm, uncoated) inhibit hepatitis B virus replication in HepAD38 
cells [44].  The suggested mechanism of inhibition is the direct interaction between 
AgNP and the HBV dsDNA or virion.  Lu et al. determined through TEM that the 10nm 
particles were able to bind directly to the HBV virion.  AgNP had little effect on HBV 
circular DNA but inhibited the formation of HBV intracellular RNA.  HBV is an 
enveloped dsDNA virus with a reverse transcription intermediate (dsDNA-RT).  HBV is 
generally spherical and 42nm in diameter (similar to DENV, 50nm) but pleomorphic 
forms exist including filamentous and spheres without a nucleocapsid core. 
Silver Ions 
It is important for AgNP research to differentiate between effects of silver 
nanoparticles and silver ions.  AgNP are widely viewed as antimicrobial, but it may 
actually be the silver ions present in the colloid that impart protective effects.  Silver ions 
(Ag+) are known to possess antibacterial effects by the mechanism is not fully 
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understood.  Silver ions are also cytotoxic at much lower concentrations than ion-free 
AgNP colloids.  Potential in-vivo treatments must utilize well-characterized silver 
colloids to ensure ion levels are safe.  Silver ions interact with thiol groups in enzymes 
and proteins, altering their intended conformation and function [46].  Ions released from 
silver nanoparticle colloids is known to inactivate enterobacter aerogenes-specific 
bacteriophage (UZ1).  Silver ions in the form of silver nitrate (AgNO3) also inactivated 
the MS2 and T2 phages and implicated in the inactivation of numerous other viruses [34], 
[47], [48].  The bactericidal effect of silver ions are well known and provide the 
antibacterial properties of silver used in medical dressings, surgical tools, and many 
commercial products [49]. 
Silver Nanoparticle Selection 
The increased attention of potential AgNP antiviral properties led to numerous studies 
regarding the influence of AgNP size, concentration, surface modification, and 
morphology on their viralcidal or cytoprotective effects [34]–[43].  Several reports 
indicate that uncoated, spherical AgNPs of approximately 10-20nm in diameter are the 
most effective at preventing viral infection in a variety of cell lines while avoiding 
significant host cell cytotoxicity [34], [38], [42].  Such particles commonly exhibit non-
cytotoxic antiviral effects at concentrations <50µg/mL. 
Stabilizing AgNP with citrate (1%) prevents aggregation and improves particle 
suspension in a colloid.  Citrate stabilizes the AgNP by creating an electrostatic barrier in 
weak complex with the particles.  Citrate is easily displaced which permits unhindered 
binding between AgNP and ligands such as sulfides on viral envelopes [50]. 
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MATERIALS AND METHODS 
Overview 
 Research was conducted in three phases: characterization, fluorescence, and 
analysis.  First, the key components of the research were characterized (Vero cells, 
AgNP, and DENV2).  Vero cells were passaged numerous times to ensure they were free 
of foreign contamination and their growth curve was determined at 24 hour intervals.  
The silver nanoparticles used in this research were analyzed for size distribution, colloid 
concentration, and aggregation.  DENV2 was propagated in Vero cells and titrated by 
plaque assay and flow cytometry.  Second, the effect of AgNP, DENV, and DENV-
AgNP were explored through immunofluorescence binding assays.  The impact of AgNP 
on DENV binding to Vero cells constituted the endpoint assay of this research.  Third, 
the fluorescent images were processed and analyzed to determine the effect of AgNP on 
DENV binding to Vero cells. 
Vero Cells 
Vero 76 cells (CRL-1587, ATCC) are African green monkey kidney epithelial 
cells.  Vero cells are commonly used in microbiology, molecular and cell biology 
research when a continuous mammalian cell line is required [51].  Vero cells are 
anchorage-dependent and susceptible to a wide range of viral infection, thus permitting 
the study of viral infection through plaque reduction assays and other common analytical 
techniques [51].  Vero cells have been used extensively with DENV and are a proven 
model for DENV experimentation [5], [26], [52]. 
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To reliably perform experiments in cell culture with repeatable results, it is 
important to accurately predict the cell population at various points.  Vero cell growth is 
commonly reported to double in each 24h period until day 6, when the growth is 
significantly slower [53].  Growth rates over 96h for the particular Vero cells used in this 
research exhibited a 12h stabilization period of attachment and 80% growth every 24h 
period over 96h (Figure 2) as determined by cell counting using the hemacytometer 
method (described below). 
Cell Line Maintenance 
Vero 76 (ATCC® CRL-1587
TM
) cells were maintained according to established 
protocols [51], [54]. Cells were maintained in DMEM/High Glucose (HyClone®) 
supplemented with 10% heat-inactivated Fetal Bovine Serum and 1% 
Penicillin/Streptomycin (Sigma®, 10k U/mL penicillin and 10mg/mL streptomycin in 
Figure 2. Vero cell 96-hour growth curve 
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0.9% NaCl).  During subculture procedures, cell count and viability was performed by 
the Trypan Blue exclusion test using a hemacytometer, described below.  This permitted 
a high consistency in cell growth timelines and cell survival.  A cell growth curve (Figure 
2) was established as a baseline for experiments influencing cellular growth rates and to 
provide greater consistency and predictability when preparing for experiments. 
Five 60mm petri dishes were seeded with Vero cells at a density of 15x104 per 
dish, as determined by the hemacytometer method of cell counting.  At 24 hour intervals, 
one culture was removed from incubation and processed for cell counting as described 
below.  The slow growth in the first 24 hours is typical since the cells take approximately 
12 hours to stabilize in the media, and undergo the process of adhesion to the dish prior to 
entering the phase of growth where they double approximately every 24 hours [53]. 
Virus Propagation 
Propagation of Dengue virus serotype 2 (DENV2-NGC) (Dr. Eric M. Vela, 
Battelle Research Center) was performed in Vero 76 cells.  The titer of virus stock was 
approximately 106 PFU/mL.  Vero 76 cells were seeded at 2x106 in 100 mm petri dishes 
in DMEM/High Glucose (HyClone®) supplemented with 10% heat-inactivated Fetal 
Bovine Serum and 1% Penicillin/Streptomycin (Sigma®, 10k U/mL penicillin and 
10mg/mL streptomycin in 0.9% NaCl).  The cells were incubated at 37oC and 5% CO2 
until they reached a confluency of approximately 90% then infected with DENV2 for 5-6 
days, which was prior to significant cytopathic effects as observed through a light 
microscope. Previous research has demonstrated that the presence of serum in the growth 
media during DENV propagation does not inhibit the titer yield but is necessary for 
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proper cell maintenance in culture [55]. The cells were then detached from the growth 
surface with Trypsin and centrifuged at 3200 rpm (2136x g) at 4oC for 10 minutes to 
eliminate cell debris. Immature (non-infectious) isoforms of DENV are primarily 
intracellular and captured in the pellet following centrifugation.  The virus recovered 
from the supernatant contain primarily mature (infectious) DENV although the various 
isoforms can never be isolated with 100% efficiency.  The supernatant was aliquoted and 
stored at −80°C until use.  Virus stock was filtered before use using 0.22µm filter 
membranes (EMD Millipore). 
Virus Quantification by Flow Cytometry 
Dengue virus titers were determined by plaque assay in confluent monolayers of 
Vero 76 cells grown in 6-well plates. Vero 76 cells were inoculated with ten-fold serial 
dilutions when monolayers reached 80 to 90% confluence. After 2 hours of viral 
adsorption, the monolayers were overlaid with 2 ml of Opti-MEM GlutaMAX (Life 
Technologies Inc.) containing 2% Methyl-cellulose (Acros Organics) and 0.5% fetal 
bovine serum. The cultures were incubated at 37 °C for 5-6 days and then counted for 
plaque formation after fixation with 4% paraformaldehyde and staining with 1% crystal 
violet solution (Sigma).  Additionally viral titers were also determined using flow 
cytometry as described by  Medina et al [26].  Briefly, Vero cells grown in 24-well plates 
at a density of 1.25x105 per well 24 hours prior to infection were infected with ten-fold 
serial dilutions of DENV2 diluted in Opti-MEM. After incubating one hour with gentle 
rocking every 15 minutes, the supernatant was aspirated and overlaid with 1ml of 2% 
methyl cellulose and incubated at 37 °C for 24 hours. Next day, infected monolayers 
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were trypsinized, fixed, blocked for unspecific binding and then stained with DENV2 
monoclonal antibody 4G2 (Millipore). These antibodies are directed to the E protein of 
the dengue virus and are capable of specifically neutralizing DENV2 serotype. Because 
these antibodies are not fluorescent tagged, the cells were stained with fluorescein 
isothiocyanate (FITC) conjugated secondary antibodies (Biolegend) and analyzed using 
Accuri C6 flow cytometer. Final viral titers were calculated as infectious units (IU)/ml. 
Silver Nanoparticle Synthesis and Filtration 
AgNPs were synthesized by the reduction of 0.4% w/v (~0.024 M) silver nitrate 
(AgNO3, MW=169.87, Sigma-Aldrich) with 0.5% w/v (~0.132 M) sodium borohydride 
(NaBH4, MW=37.83, Sigma-Aldrich) in an aqueous matrix, stabilized by 1.0% w/v (~0.034 
M) trisodium citrate dihydrate (Na3C6H5O7·2H2O, MW=294.10, Fluka).  In a dark chemical 
fume hood, 50mL of 4°C de-ionized water and 1.25mL of 0.4% silver nitrate were 
combined and mixed with a magnetic stirrer for 1 minute.  500uL of 0.5% sodium 
borohydride was rapidly added to the sidewall of the solution while mixing vigorously 
for 1 minute.  After 1 minute, 200uL of 1% sodium citrate was added and continuously 
stirred for an additional 1 minute.  The solution was placed in a foil covered 50 mL 
conical tube and kept stored at 4°C until use. 
This synthesis results in a colloid containing spherical AgNPs with a mean 
diameter of 8nm.  This method also results in trace amounts of non-reduced silver ions 
following the formation of AgNPs.  Silver ions were removed through tangential flow 
filtration. 
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  Tangential flow filtration (TFF) was employed to size-select AgNPs for viral 
inhibition studies.  Typically reserved for biological separations, TFF operates on the 
continuous recirculation of a solution containing an analyte of interest across a porous 
membrane (Figure 3).  As a solution or colloid is passed over the membrane, larger 
components are retained by the filter membrane and kept within the recirculation tubing 
(e.g. gray spheres in Figure 3) while constituents smaller than the filter pores are passed 
through the membrane and collected in a dilute filtrate (e.g. blue spheres in Figure 3). 
  By employing filters of varying pore size, AgNPs were size-selected for diameters 
of approximately 5-20nm (8nm average) and concentrated by removing excess solvent 
using membranes with ultrafine pore sizes (e.g., 5nm in diameter).  The TFF process 
Figure 3. Schematic depicting a typical TFF set-up for the filtration of colloidal 
AgNPs.  Gray and blue spheres represent AgNPs larger and smaller than the filter 
membrane pores, respectively. 
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AgNP-DENV2 Treatment 
Silver nanoparticles were incubated with DENV2 at room temperature in various 
concentrations (10, 25, 50, 100µg/mL) for one hour prior to Vero cell infection.  This 
pre-treatment timeline was chosen in order to allow stable binding between DENV2 and 
the AgNP. 
Trypan Blue Exclusion Test (Hemacytometer method) 
Trypan Blue staining was performed during cell culture to ensure continued 
viability of the Vero cells between passages.  Trypan Blue staining was also performed to 
support the results of MTT assays (cell viability).  After centrifugation, cells were 
suspended in DMEM and titurated thoroughly.  A hemacytometer was cleaned with 70% 
ethanol and a 20mm glass coverslip was placed over the viewing grid.  50µL of the cell 
suspension was added to 100µL Trypan Blue stain in a 0.5mL centrifuge tube and 
titurated thoroughly.  This 50:100 ratio provided a dilution factor of 3.  The cell-stain 
mixture was pipetted into the loading channel until the viewing grid was full 
(approximately 10µL).  Viable cells exclude the stain and appear white while dead cells 
take up the stain and appear blue.  Eight grids were counted (living/dead) to provide cell 
viability as a percentage of total cells.  Estimated cell count was determined by the 
formula: 
𝑉𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
=
# 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
# 𝑔𝑟𝑖𝑑𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ∗ 104 
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hours at 37oC and 5% CO2.  Following incubation and visual confirmation of the 
formation of purple formazan crystals in mock treated wells, the MTT/HEPES solution 
was carefully aspirated and the crystals were solubilized with 100µL dimethyl sulfoxide.  
After 15 minutes, the absorbance of each well was read at 570nm (Figure 7) with a 
background of 620nm in a spectrophotometer with 3 reads per well following 30 seconds 
of slow orbital rotation and 10 seconds of settling time.  Quantitative results are averages 
of four measurements under the same conditions. 
Biocompatibility of AgNPs in Vero cells 
 The biocompatibility of silver nanoparticles versus silver ions were determined 
through MTT assay.  Vero cells were seeded at 2x104 cells/well in a 96-well plate in 
DMEM-10 and incubated at 37oC and 5% CO2. The cells were allowed to stabilize for 24 
hours under these conditions prior to treatment.  After 24 hours, the cells were exposed to 
AgNP or silver nitrate (AgNO3) in concentrations of 100µg/mL, 50µg/mL, and 10µg/mL, 
for 24 hours.  MTT assay was performed as described above. 
Virus Binding Study 
To assess the influence of AgNP in the binding of DENV to target cells, a cold-
binding study was conducted.  The first steps in the viral life cycle are binding to a target 
cells and entry into that cell by virus-dependent mechanisms. DENV is able to undergo 
cell-binding events at 4oC but entry (by clatherin-mediated endocytosis) is not permitted 
at this low temperature. 
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Vero cells were seeded at 3x104 cells/well in a 12-well μ-slide (Ibidi(R)) for 24 
hours.  Experimental treatments (AgNP-DENV, DENV, and AgNP) were prepared at 
room temperature for one hour.  The AgNP-treated DENV treatment was co-incubated 
for one hour at room temperature to permit binding of AgNP to DENV.  Volumes of 
AgNP and DENV used in the co-incubation were calculated to provide the desired AgNP 
concentration and DENV multiplicity of infection (MOI).  The required virus inoculum 
was calculated using the formula: 
(𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙)(𝑀𝑂𝐼)
(𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟, 𝑝𝑓𝑢)
∗ 1000µ𝐿 = (𝑖𝑛𝑛𝑜𝑐𝑢𝑙𝑢𝑚)µ𝐿 
Cells and treatments were cooled to 4oC for 15 minutes.  The treatments were incubated 
with cells for one hour at 4oC.  Slides were gently rocked every 15 minutes during 
treatment.  Following cold incubation, cells were gently washed three times with PBS 
(4oC) to remove unbound DENV and/or AgNP.  Control cells were also washed in the 
same manner.  Treatments and washes were removed by pouring onto an absorbent 
towel.1  Cells were fixed with chilled 4% paraformaldehyde to prevent the internalization 
of DENV and AgNP.  Indirect fluorescence (without Triton-X permeabilization) was 
performed to visualize the effects of AgNP on DENV binding to target cells. 
Cells were washed three times with PBS.  Primary antibody was diluted 1:300 per 
manufacturer specifications and incubated with cells for one hour at 37oC or overnight at 
4oC.  The primary antibody used was the Anti-Dengue Virus Serotype 2 Antibody, clone 
3H5-1 of mouse origin (MAB8702 Chemicon, Hampshire, United Kingdom).  As an 
                                                 
1 Vacuum aspiration repeatedly removed cells in early trials  
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isotype control, normal mouse IgG (NI03, Calbiochem®) was added in place of the 3H5 
in one well. 
Following incubation, the primary antibody was removed and cells were washed 
three times with chilled PBS.  Secondary antibody was diluted and added to cells for one 
hour at 37oC or overnight at 4oC.  The secondary antibody was rabbit anti-mouse IgG-
FITC.  The secondary antibody was removed and cells washed three times with chilled 
PBS.  Cells were counter-stained with Texas Red®-X Phalloidin for 10 minutes to 
visualize the polymerized F-actin cytoskeleton of the cells.  Cells were washed three 
times with chilled PBS and a cover slip was mounted using Vectashield® H-1500 which 
contains DAPI (4',6-diamidino-2-phenylindole, blue) for nuclear visualization.  
Visualization was performed on an 
Olympus inverted fluorescence microscope 
with a CytoViva® Dual Mode Fluorescence 
system (Figure 8), which provided 
enhanced visualization of the AgNP.  
Exposure time required for image capture 
varied for each fluorescent stain.  The 
optimal values found for these assays were 
TRITC (tetramethylrhodamine, red) 500ms 
and FITC (Fluorescein isothiocyanate, 
green) 1900ms.  Optical and software settings were identical when capturing images and 
not enhanced to artificially increase or decrease fluorescence. 
Figure 8. CytoViva Dual Mode Fluorescence System, AFRL, 
711th HPW. 
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Blocking Non-Specific Binding During Immunofluorescence 
 During indirect immunofluorescence procedures, the decision was made to 
exclude the common blocking step.  Traditionally, cells are incubated with bovine serum 
albumin (BSA) and serum matching the host of the secondary antibody to block the non-
specific binding of antibodies to cell Fc receptors.  According to research by Igor 
Buchwalow, et al, there were no significant differences between various samples that 
received or did not receive blocking treatment [23].  Buchwalow demonstrated that the 
standard fixation step removes the ability of endogenous Fc receptors to bind the Fc 
portion of antibodies.  This result was confirmed during early fluorescence trials where 
blocked and non-blocked samples were compared under the same experimental 
conditions.  In the absence of blocking, background staining was never observed.  This 
decision saved time and lab resources and add further credibility to the suggestion that 
protein blocking steps, although commonplace in laboratories, are unnecessary. 
Image Processing and Analysis 
For purposes of this research and the virus binding study, the green (FITC) 
fluorescent intensity represents the level of DENV attachment to the surface of Vero 
cells.  Image processing methods were used to isolate the fluorescent region of interest 
(ROI) and remove the background and artifacts.  Image analysis methods were used to 
quantify the differences between ROI.  The relative difference in fluorescence intensity 
between images provided quantifiable differences between the level of DENV binding to 
cells.  Immunofluorescent images were processed and analyzed in ImageJ (National 
Institutes of Health, http://imagej.nih.gov/ij/).  Detailed screenshots of the image 
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processing and analysis steps are contained in Appendix B.  Image processing and 
analysis was conducted using procedures established for the quantification of 
fluorescence which are accepted within the microscopy community. 
The aim of the image processing steps is to isolate the fluorescence that best 
represents the presence of DENV bound to cell surface receptors.  Processing is based on 
the concept of lookup tables (LUT).  Within ImageJ, a color image is converted to an 8-
bit image.  A single color (green) 8-bit LUT represents 256 possible shades (bins) of 
green.  A LUT value of zero represent black and 255 represents pure green.  The 
fluorescent ROI falls between bins 0-255 but would be impossible to identify with the 
naked eye.  The image processing and analysis steps are described below and 
summarized in Figure 9: 
Figure 9. Image processing and analysis overview 
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1. Convert single-color image to 8-bit.  While other image depths are available (i.e. 
24-bit, with range 0-4095), the additional resolution is not required for this analysis. 
2. Subtract background.  Background subtraction is extremely important when 
quantifying image intensities.  This operation removes constant pixel information from a 
continuous background (Figure 10).  This does not remove the presence of fluorescent 
artifacts (Figure 11).  Artifacts represent areas with high intensity that were not caused by 
the binding of fluorescently-tagged secondary antibodies to DENV (actually to the 
primary antibodies bound to DENV E-protein).  If artifacts are included in the analysis, 
they would skew the results and represent greater levels of bound DENV than there truly 
are. 
3. Identify exclusion regions.  Before measuring the fluorescence intensity of an 
image, the pixel values (bins 0-255) of the exclusion regions must be identified.  The two 
Figure 10. Sample background subtraction in ImageJ. A) Original greyscale image and histogram, 
B) Image with background subtracted and associated changes to the histogram. 
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exclusion regions are the black background and the bight, saturated artifacts.  The pixel 
values representative of these regions are identified through the histograms of selection 
areas that only include the area types to exclude.  Image histograms graphically represent 
the number of occurrences of each pixel value, with each pixel providing one count.  
Analyzing the pixel values of black areas far from an ROI will provide the pixel values 
representing black background.  Analyzing the pixel values of highly saturated artifacts 
will provide the pixel values representing false fluorescence intensity that needs to be 
excluded from final analysis (Figure 11).  Repeated measurements identified that pixel 
Figure 11. Identification of exclusion regions for black and artifact intensity. 
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values from 0-8 represent black and values from 198-255 are present only in the artifacts.  
In each image, the final range of pixel values representing the ROI were bins 9-197.   
4. Isolate the threshold (ROI) using the limits of black maximum and artifact 
minimum.  Within the ImageJ Threshold feature, the pixel values are set to the 9-197 
range mentioned above.  Thresholding the image to this range creates a binary image 
where excluded pixels are given a value of 0 and included pixels are given a value of 255.  
At this point, the image is composed of area that will or will not be included in analysis.  
This technique does not differentiate between strong fluorescence and weak fluorescence 
directly, but is used to determine the visible surface area that contains fluorescent values 
(from original image) determined to be valid intensities.  The qualifying area represents 
the ROI.  The thresholding function creates closed objects within which is a portion of 
the total ROI.  Image analysis techniques are next used to measure the total area 
contained within these ROI “islands” and other properties related to size and distribution. 
5. Analyze images.  The target metrics are total ROI area (sq. pixels) and cell count.  
The Measure Particles function within ImageJ calculates the area of individual ROI 
islands and provides an image total.  Knowing the total area in the image that contained 
qualifying pixel intensity is required, but does not present the whole story.  If the pixel 
intensity is held constant, an image with more cells should have greater area of ROI.  
Normalizing an image’s ROI area with cell count provides a more accurate estimate of 
DENV binding per cell.  The Cell Counter tool was utilized to count the number of cells 
in each image.  If the normalized region of interest (nROI) is reduced from one image to 
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the next, it is reasonable to conclude that only the different experimental conditions 
contributed to the reduction. 
RESULTS 
Cytotoxicity of DENV Infection of Vero Cells 
The effect of DENV infection of Vero cells was analyzed to confirm the 
infectivity of DENV virus stock and serve as a baseline for virus inhibition studies.  
Following DENV infection (MOI 0.1), Vero cell viability decreased rapidly from 36-72 
hours compared to non-infected cells (Figure 12).  By 120hpi, the viability of infected 
and noninfected cells was comparatively low.  Based on visual comparison, the infected 
cells experienced cytopathic effects and had lifted from the growth surface in patches.  
The noninfected cells had overgrown and become weakly adherent to the growth surface 
Figure 12. Viability of DENV infected Vero cells. 
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and were removed from the wells by the gentle force of media aspiration.  While the cell 
viability at 120hpi is similar, it was due to opposing conditions; the Vero cells began to 
overgrow and die while the DENV infected cells died from infection and lifted from the 
petri dishes in clusters. 
This decline in cell viability was expected, as Vero cells do not have innate 
defenses against infection.  Since Vero cells are highly permissible of DENV infection, 
they are commonly used to propagate DENV stock during research. 
Biocompatibility of AgNPs in Vero cells 
 Cell viability measured by MTT assay demonstrated that increasing the 
concentration of AgNP from 10-100µg/mL decreases cell viability relative to mock 
Figure 13. Cytotoxicity of silver nanoparticles (AgNP) versus silver ions (Ag+) at in 
concentrations of 100µg/mL, 50µg/mL, and 10µg/mL. 
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treated cells.  Positive controls (silver ions, Ag+) in the same concentrations yielded much 
greater cytotoxicity than AgNP, with the exception of Ag+ (10µg/mL), which had higher 
viability than AgNP.   The results suggest that AgNP stock colloid does not have a high 
concentration of silver ions and that AgNP concentrations should be selected to be as low 
as possible to minimize cytotoxic effects while providing antiviral or cytoprotective 
effect from viral infection. 
AgNP Inhibition of DENV Binding 
 Vero cells were incubated with treatments (AgNP-DENV, DENV only, AgNP 
only) in 4oC to permit binding but inhibit internalization of AgNP and DENV.  Based on 
immunofluorescence analysis, DENV (MOI 40) pretreated with AgNP (25µg/mL), 
resulted in far fewer bound virion compared to DENV infection without AgNP treatment 
(positive control) and negative controls (data not shown).  Untreated DENV presents 
greater green fluorescence than after AgNP treatment (Figure 14).  Fluorescence images 
were captured at identical optical and processing software settings. 
 The reduction in FITC intensity was evaluated in ImageJ as previously described.  
DENV pretreatment with AgNP (10 and 25µg/mL) reduced fluorescence below the levels 
of the mock treated and isotype controls (Figure 15).  Compared to DENV-only, 
pretreatment with 10µg/mL reduced DENV binding by a factor of 23.2.  Pretreatment 
with 25µg/mL reduced DENV binding by a factor of 12.2. 
Interestingly, the higher concentration of AgNP (25µg/mL) resulted in 
approximately twice the fluorescence intensity of the lower concentration (10µg/mL).  
One possible reason this occurred is that higher AgNP concentrations contributed to 
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increased agglomeration.  This could reduce the effective number of AgNP available to 
bind with DENV particles and therefore lead to reduced DENV binding inhibition.  
Regardless, of the cause of this effect, both AgNP treatments led to fluorescence 
intensities that were not significantly different than the mock treated control (P<0.05). 
Comparison of the normalized ROI (nROI) histograms revealed statistically 
significant differences (P<0.05, ANOVA) in the fluorescence intensity of treated cells 
and controls, and between the AgNP-treated DENV and DENV-only treatments. 
While cold incubation does not reflect in vivo conditions during infection, this 
condition is effective when attempting to isolate the step at which AgNP may inhibit the 
DENV life cycle.  These results are similar to research showing AgNP inhibition of 
various viruses at the binding and entry phase of viral replication.  However, this is the 
first time a Group IV virus (ss(-)RNA) has been inhibited by AgNP. 
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Statistical Analysis 
 SigmaPlot 12.0 software (Systat & Mystat Products, Chicago, IL) was used to create 
graphs and perform statistical analysis.  Experimental conditions were compared to mock-
treated controls as percent of control.  Fluorescent images were also compared to the isotype 
control to remove the influence of background staining.  ImageJ was used to process images 
as described above. 
 Histograms representing fluorescence intensities within the ROI were compared 
using the Mann-Whitney rank sum test.  As expected, each histogram failed the normality 
test (Shapiro-Wilk), therefore, the Mann-Whitney rank sum test provided greater descriptive 
efficiency than the paired t test. 
Figure 15. Fluorescence intensity per cell.  The isotype control and both AgNP 
concentrations did not produce fluorescence intensity significantly different from control 
(P<0.05).  DENV-only fluorescence was statistically significant compared to control and 
both AgNP concentrations (P>0.05). 
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CONCLUSION 
This research examined the ability of 8nm silver nanoparticles to inhibit the 
binding event of dengue virus to Vero cells in vitro.  During the course of this research, 
silver nanoparticles were synthesized, purified, and characterized.  Dengue virus type 2 
was propagated in Vero cells, quantified and verified for virulence, and purified of 
bacterial/fungal contaminants.  The biocompatibility of AgNP and Vero cells were 
measured and compared to silver nitrate.  The influences of AgNP in the binding event of 
DENV to Vero cells was visualized through indirect immunofluorescence and quantified 
through histogram analysis. 
The null hypothesis of this study was that silver nanoparticles do not inhibit the 
binding step of the dengue virus serotype 2 (DENV2) replication cycle in Vero 76 cells, 
inferred through similar fluorescence intensity visualization.  Results indicate that AgNP-
pretreated DENV produced a statistically significant reduction in fluorescence intensity 
compared to DENV infection without AgNP pretreatment (P<0.05).  Therefore, the null 
hypothesis is rejected. 
This research presents, for the first time that DENV binding to Vero cells is 
inhibited by 8nm AgNP (citrate stabilized).  Fluorescence intensity was 96% (10 µg/mL 
AgNP) and 92% (25µg/mL AgNP) in AgNP-treated DENV compared to untreated 
DENV-only infection of Vero cells.  A limitation of this study is that the mechanism of 
binding inhibition is unknown.  Existing knowledge on AgNP interaction with viral 
envelopes suggests that AgNP bind to DENV disulfide regions and possibly others.  This 
could inhibit binding by preventing receptor-epitope covalent interactions.  However, it is 
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possible that unbound AgNP in the AgNP-DENV colloid coat the cells and prevent 
DENV binding in a cytoprotective manner, rather than an antiviral agent. 
This serves as a stepping off point for further research into the interaction of 
AgNP and DENV.  Continued research could include: 
 Development of a technique to filter unbound AgNP from the AgNP-DENV colloid 
to prevent unbound AgNP from binding to cells 
 Examining the mechanism of binding inhibition by confirming AgNP-DENV binding 
through TEM/SEM 
 Measure cell viability throughout the course of DENV infection versus AgNP-
DENV, measured by MTT assay 
 Uses of AgNP to disrupt the disease cycle in Aedes mosquitoes 
 Progeny virus production following AgNP-treated DENV infection of Vero cells or 
macrophages, measured by using supernatants from infected cultures to infect second 
set of cell cultures, quantified by either flow cytometry or MTT assay 
 Changes in DENV protein production, measured through Western blot after DENV 
infection 
 Impact of AgNP during DENV infection of macrophages (target cells) 
 Quantification of DENV infection after AgNP treatment, measured by flow 
cytometry 
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APPENDIX A – AgNP Characterization 
Figure 16. AgNP size distribution by intensity, Z-avg 23.5nm +0.95nm. 
Figure 17.  ICP-OES Calibration curve 
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